SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
This is a phase I/II dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA-I&T (also known as PNT2002). The two study drugs are 225Ac-J591 and 177Lu-PSMA-I&T. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells). The first phase of the study (phase I) will determine the highest dose of the study drug that can be safely given. The second phase of the study (phase II) will determine the effectiveness of the drug combination in patients with prostate cancer.
Principal Investigator: Dr. Medhat Osman
To learn more about SPLASH and how you can join contact our research office at (314) 289-7690
This study is funded by the Foundation through POINT Biopharma
Principal Investigator: Dr. Medhat Osman
To learn more about SPLASH and how you can join contact our research office at (314) 289-7690
This study is funded by the Foundation through POINT Biopharma